Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$27.85
-$0.86(-3.93%)
At close: 4:00 PM EST
$27.85
-$0.86(-3.93%)
Day’s Range― - ―
52-Week Range$15.93 - $43.66
Previous CloseN/A
Volume20.02K
Average Volume (3M)281.19K
Market Cap
$743.47M
Enterprise Value$371.51M
Total Cash (Recent Filing)$243.18M
Total Debt (Recent Filing)$9.13M
Price to Earnings (P/E)―
Beta3.06
Next Earnings
Aug 07, 2026EPS Estimate
-1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.03
Shares Outstanding19,926,900
10 Day Avg. Volume349,906
30 Day Avg. Volume281,189
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.71
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
$80.71Price Target Upside189.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low-leverage Balance SheetA very low debt-to-equity (~0.04) and substantial equity provide durable financial flexibility for a clinical-stage biotech. This reduces solvency risk, supports multi-year R&D investment without immediate debt pressure, and improves ability to fund trials or pursue partnerships over the next 2–6 months.
Extended Cash RunwayThe announced equity and warrant financing that is expected to deliver roughly $134.8M of net proceeds materially extends runway into Q1 2029. This lengthened funding visibility lowers near-term refinancing risk and enables execution of registrational programs and preparatory commercial work.
Advancing NGN-401 Clinical ProgramCompletion of Embolden dosing plus Phase 1/2 long-term data showing sustained developmental milestone gains and favorable tolerability materially de-risks the lead asset. Durable, multidomain improvements and absence of major safety signals support a clearer path toward regulatory submission and future commercial potential.
Bears Say
High Cash BurnThe company exhibits material negative operating and free cash flows, with burn accelerating into recent years. Persistent cash outflows make the business structurally dependent on external financing to sustain trials and operations, increasing dilution and funding risk absent sustained progress or partner deals.
No Recurring Product RevenueAs a pre-commercial biotech, Neurogene lacks material product revenue and relies on equity financings and interest. This structural absence of operating revenue leaves long-term sustainability contingent on successful trial outcomes, commercialization execution, or repeated capital raises.
Widening Net Losses And Negative ReturnsNet losses have grown materially over recent periods and returns on equity are substantially negative, eroding shareholders' equity and increasing future financing needs. Persistent losses signal extended pre-commercial spend and pressure on long-term profitability unless programs convert to revenue.
Neurogene News
NGNE FAQ
What was Neurogene Inc.’s price range in the past 12 months?
Neurogene Inc. lowest stock price was $15.93 and its highest was $43.66 in the past 12 months.
What is Neurogene Inc.’s market cap?
Neurogene Inc.’s market cap is $743.47M.
When is Neurogene Inc.’s upcoming earnings report date?
Neurogene Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 17 days.
How were Neurogene Inc.’s earnings last quarter?
Neurogene Inc. released its earnings results on May 12, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.296 by -$0.094.
Is Neurogene Inc. overvalued?
According to Wall Street analysts Neurogene Inc.’s price is currently Undervalued.
Does Neurogene Inc. pay dividends?
Neurogene Inc. does not currently pay dividends.
What is Neurogene Inc.’s EPS estimate?
Neurogene Inc.’s EPS estimate is -1.42.
How many shares outstanding does Neurogene Inc. have?
Neurogene Inc. has 19,926,900 shares outstanding.
What happened to Neurogene Inc.’s price movement after its last earnings report?
Neurogene Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.296. Following the earnings report the stock price went up 3.424%.
Which hedge fund is a major shareholder of Neurogene Inc.?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.71 (189.82% Upside)
$80.71 (189.82% Upside)
Blogger Sentiment
Bearish
NGNE Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.9%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.54%
Trailing 12-Months
Company Description
Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$80.71
▲(189.82% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
7.38% Insiders
6.61% Mutual Funds
54.83% Other Institutional Investors
23.59% Public Companies and
Individual Investors